Please check your internet connection and try again.
# Mega CV (Amoxicillin/Potassium Clavulanate)
## Overview
Mega CV is a combination antibiotic consisting of amoxicillin (a beta-lactam) and potassium clavulanate (a beta-lactamase inhibitor). The clavulanate component extends the spectrum of coverage to include beta-lactamase-producing organisms.
## Primary Indications
* Community-acquired pneumonia
* Acute bacterial sinusitis
* Acute otitis media (AOM)
* Skin and skin structure infections
* Urinary tract infections (UTIs)
## Adult Dosing
* **Standard dosing:** 500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours.
* **Severe infection/Respiratory tract:** 875 mg/125 mg orally every 12 hours.
* **Extended release (XR):** 2000 mg/125 mg twice daily.
## Pediatric Dosing
* **General dosing (based on amoxicillin content):** 20–45 mg/kg/day divided every 8–12 hours depending on indication.
* **Acute Otitis Media (AOM):** 90 mg/kg/day (amoxicillin component) divided every 12 hours, using the 7:1 ratio product to minimize clavulanate exposure and diarrhea risk.
* *Note: Dosing must be based on local resistance patterns and specific formulation (e.g., 200 mg/5 mL vs 400 mg/5 mL suspensions).*
## Dose Adjustments
* **Renal Impairment:** Reduce dosage or frequency if CrCl < 30 mL/min. Avoid the 875 mg tablet in patients with CrCl < 30 mL/min as it cannot be adjusted.
* **Hepatic Impairment:** Use with caution; monitor hepatic function periodically.
## Contraindications
* History of serious hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins.
* History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin/clavulanate therapy.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, skin rash (non-allergic).
* **Serious:** Clostridioides difficile-associated diarrhea (CDAD), hepatotoxicity (more common in males and elderly), anaphylaxis.
## Key Drug Interactions
* **Warfarin:** May increase INR/bleeding risk; monitor INR closely.
* **Methotrexate:** May decrease clearance of methotrexate, increasing risk of toxicity.
* **Oral Contraceptives:** May reduce efficacy; recommend barrier protection during therapy.
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, increasing serum concentrations.
## Monitoring
* Monitor for signs of allergic reaction (rash, wheezing).
* Monitor renal and hepatic function during prolonged therapy (> 10 days).
* Assess patients for watery or bloody stools (r/o *C. difficile*).
## Clinical Pearls
* **Take with food:** Administer at the start of a meal to improve absorption and minimize gastrointestinal distress.
* **Formulation Warning:** Not all formulations are bioequivalent. Do not substitute 250 mg tablets for 250 mg chewable tablets due to differences in clavulanate content.
* **Duration:** Use the shortest duration necessary to minimize risk of antibiotic resistance and adverse effects.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify doses, contraindications, and drug interactions against current local institutional protocols, package inserts, and clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
